Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

lastige vent, maar stapje voor stapje

1 Post
| Omlaag ↓
  1. [verwijderd] 20 juni 2007 21:08
    Bush Will Pair Veto With New Cell Initiative
    Sign In to E-Mail or Save This
    Print
    Reprints
    Share
    Digg
    Facebook
    Newsvine
    Permalink


    By SHERYL GAY STOLBERG
    Published: June 20, 2007
    WASHINGTON, June 19 — President Bush will issue an executive order intended to encourage scientific advances in regenerative medicine, according to senior White House officials who said Mr. Bush would announce the initiative on Wednesday, just as he vetoes a measure promoting embryonic stem cell research.

    The embryonic stem cell measure has widespread public support, and the veto would be the second time Mr. Bush has rejected it. By pairing the veto with a new scientific initiative, the White House clearly hopes to blunt the inevitable criticism that Mr. Bush will face from researchers, advocates for patients and politicians, including many in his own party.

    In interviews on Tuesday, two senior administration officials said Mr. Bush would direct his health and human services secretary to promote research into producing cells with properties akin to those of human embryonic stem cells, without destroying embryos in the process. Mr. Bush has said embryo destruction is a moral line that he will not cross.

    The officials said Mr. Bush wanted the National Institutes of Health to capitalize on recent scientific advances, including a study published this month involving skin cells in mice, that had the potential to sidestep the ethical controversies surrounding embryonic stem cell experiments. The White House has been consulting with scientists in recent weeks on the plan, they said.

    “This is the product of a lot of really hard, earnest work on this policy,” said Karl Zinsmeister, a domestic policy adviser to Mr. Bush who helped develop the initiative. “It is a real sincere effort to open up a new scientific solution to a vexing problem.”

    But the effort appears largely symbolic — there is no money attached — and some scientists were instantly skeptical. Two leading stem cell researchers, interviewed Tuesday evening, said the recent work was no substitute for embryonic stem cell research. One, Douglas A. Melton of Harvard University, said he had become aware recently that the White House was trying to reach out to some of his colleagues who are pursuing the skin cell research, which has not been replicated in humans.

    “It should be pursued just as actively as we pursue human embryonic stem cell research,” Dr. Melton said of the recent studies. “I’m not trying to say there’s nothing to this,” he continued, “but it doesn’t need any special attention from the White House. All we’ve ever asked is let human embryonic stem cell research vie for public funding like all other research.”

    Tony Fratto, deputy White House press secretary, said the new initiative was “not about politics. It’s about achieving effective policy.”

    Controversy over human embryonic stem cell studies has been a theme in the Bush presidency. The cells are considered valuable because they are “pluripotent,” meaning they can develop into any type of tissue in the body, and might therefore yield treatments and cures. In August 2001, Mr. Bush said he would allow taxpayers to finance the research, but only on stem cell colonies, called lines, that already existed.

    Scientists and advocates for patients have been pressing Mr. Bush to lift those restrictions. On Tuesday, two senior administration officials, speaking anonymously because the president had not yet announced his new initiative, summoned a reporter to the White House to share details of the alternative plan.

    They said the initiative had three parts.

    First, Mr. Bush will an announce that the registry of embryonic stem cell lines eligible for research with federal tax dollars will be reconfigured as the “human pluripotent stem cell registry,” a change intended to allow other types of stem cells to become eligible for federal financing if they have the same properties as embryonic stem cells.

    Mr. Bush will also order Michael O. Leavitt, secretary of health and human services, to “support alternative techniques,” the officials said. He will instruct Mr. Leavitt to come up with a plan describing how scientists and researchers who want to get new stem cell lines approved for the registry might do so.

    The officials said the White House was particularly encouraged by several new avenues of research, including studies involving stem cells obtained from amniotic fluid, and efforts to extract stem cells from embryos that had been declared “clinically dead.”

    But scientists said those studies could be as ethically problematic as the ones Mr. Bush already opposes. John Gearhart, a stem cell researcher at Johns Hopkins University, said no one had figured out when an embryo could be declared clinically dead. The White House officials said it would be up to the health institutes to develop standards.

    “It is not an alternative for embryonic stem cell research, because some of these alternative procedures still have ethical issues associated with them,” Dr. Gearhart said, adding, “Who is the god that says the embryo is dead?”

    More Articles in Washington »
1 Post
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.106
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.078
ABO-Group 1 23
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.829
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.804
Aedifica 3 925
Aegon 3.258 323.042
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.349
Air France - KLM 1.025 35.265
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.180
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.748
AMG 971 134.231
AMS 3 73
Amsterdam Commodities 305 6.744
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 495
Antonov 22.632 153.605
Aperam 92 15.047
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.798
Arcelor Mittal 2.034 320.943
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.597
ASML 1.766 109.805
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.834
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.447

Macro & Bedrijfsagenda

  1. 24 maart

    1. Samengestelde inkoopmanagersindex maart (Jap)
    2. Samengestelde inkoopmanagersindex maart (Fra)
    3. Samengestelde inkoopmanagersindex maart (Dld)
    4. Samengestelde inkoopmanagersindex maart (eur)
    5. Samengestelde inkoopmanagersindex maart (VK)
    6. Chicago Fed index februari (VS)
    7. Samengestelde inkoopmanagersindex maart (VS)
  2. 25 maart

    1. Ifo ondernemersvertrouwen maart (Dld)
    2. Case Shiller huizenprijzen januari (VS)
    3. Shell beleggersdag
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht